Home 2019-07-25T13:43:24+00:00

Make a  second surgical intervention unnecessary with biodegradable magnesium

A broken bone is always an unpleasant experience. Understandably enough, therefore, after successful bone healing one would be glad to simply forget about surgical procedures and orthopaedic implants once and for all. BRI.Tech enables you to do so by making a second operation unnecessary: the biodegradable implants we develop do not need to be removed later on. The whole secret lies in using elements which are naturally present in the human body and will in due course dissolve without further intervention.


Monday – Friday 9:00 – 17:00

 +43(0) 664 5065411

Welcome to BRI.Tech GmbH

BRI.Tech is breaking new ground in orthopaedic and trauma surgery. If you are curious to know how, check out below.


+++ 16.04.2019: Bioretec Ltd. completes an acquisition of BRI.Tech GmbH +++

Tampere, Finland, 16th of April 2019. Bioretec Ltd., a Finnish medical device company focused on development, manufacturing and sales of bioresorbable and bioactive surgical implants for orthopedic and trauma care has completed an acquisition of all outstanding shares of BRI.Tech GmbH located in Graz, Austria.

BRI.Tech has successfully developed and patented a novel biocompatible and bioresorbable metal composition. Products manufactured from this novel composition are currently under testing in first human clinical studies. This novel bioresorbable metal composition has been proven to have superior material properties over the first generation bioresorbable metal compositions during development and pre-clincal steps.

“I am excited to welcome the experienced team of BRI.Tech to join our Bioretec group. This is again one important step in our selected strategy to become the world’s only company having know-how, experience, manufacturing and commercialization capabilities from all of the most innovative fully resorbable materials available in the world. We have a long history of manufacturing and commercilalization our patented self-reinforced biopolymer product platform, we have on-going projects to include also fiber-reinforced biopolymer composites into our product offering and now through this acquisition we will be adding another novel material option, resorbable metals, into our product portfolio”, says Tomi Numminen, Executive Chairman of the Board of Directors of Bioretec.

“Bioretec is recognized as one of the pioneers in the field of resorbable orthopaedic implants. For us this transaction with Bioretec represents an excellent opportunity to continue our efforts in bringing our novel resorbable metal products into the markets. Bioretec has a long and proven history being able to develop, register and commercialize innovative products into the field of orthopaedic products. I am confident that by joining Bioretec group, we will be able to speed up and secure our first product launches and we shall together, in collaboration with our teams, achieve our ambitious targets set“, comments Prof. Dr. Annelie Weinberg, founder and majority shareholder of BRI.Tech.

Download: Press release – Bioretec acquires BRI.Tech 2019-04-16 (PDF)

+++ BRI.Tech is part of the EU project MgSafe +++

To watch the German version of the MgSAFE video on Youtube click here

Within the EU project MgSafe scientists want to improve current imaging technologies to enhance the visibility of magensium implants in the bone during post surgury check ups.
Find more information on: www.mgsafe.eu

+++ BRI.Tech hat es unter fast 300 Teilnehmern in die Top-10 des Gründerwettbewerbs start me up! der Zeitung BILANZ geschafft! +++

Am 07. Juni wurden wir nach Berlin eingeladen und konnten unsere Firma einem großen Publikum präsentieren. Dank dieses Erfolges, berichtet die Zeitung BILANZ in ihrer aktuellen Ausgabe über uns und bei welt.de findet sich ebenfalls ein Artikel!

+++ 7.12. 2017: BRI.Tech was featured in the Kleine Zeitung PRIMUS section – „Steirische Innovation: Streit um magische Schraube“ +++

Read more at: www.kleinezeitung.at.

© BG/Großschädl

+++ 7.12. 2017: Check out the award ceremony for the SFG company of the month November 2017 +++

A big thank you goes to all of our supporters!

© www.sfg.at

+++ 1.12.2017: BRI.Tech has won the competitionCompany of the month“ for November 2017 +++

We are proud of this result and would like to thank all our supporters! Check it out at unternehmen-des-monats.at.

Starring Prof. Annelie-Martina Weinberg and Nicole Grün, PhD


BRI.Tech was founded by a diverse team with expertise in clinical medicine, medical research, and engineering.

Tomi Numminen
Tomi NumminenCEO
Mr. Numminen has more than two decades of international healthcare experience including management, corporate development, strategy, commercialization and sales operations. He has also experience from working in the board of directors in several healthcare companies.
Assoz. Prof. Dr. Annelie-Martina Weinberg
Assoz. Prof. Dr. Annelie-Martina WeinbergCEO and Co-Founder
Annelie is a senior physician at the University Hospital Graz. In 2001, she was the first woman in the trauma surgery department to be awarded the habilitation. Besides that, she has made a name for herself by doing pioneering research in experimental biomechanics, molecular biology, and fracture healing in children, with a focus on absorbable implants. Her lifetime project is the realisation of the Laura Bassi Centre BRIC (Bioresorbable Implants for Children) at the Medical University of Graz: “I had been doing research on absorbable implants for children for several years – without sufficient financial support because the industry did not consider children worth investing in. But now things have changed. BRIC has given me the opportunity to hand down my knowledge to the next generation of researchers, to dedicate myself to scientific innovation.”
Ing. Heinz Moitzi
Ing. Heinz MoitziCo-Founder and Technical Advisor
Heinz has been working at AT&S (Austria Technologie & Systemtechnik AG) since 1981, initially as head of the mechanics and galvanics department, then as production and plant manager at Hinterberg. As the company’s manager and COO, he spent several years in Shanghai and then returned to the position of Vice President of Production; currently, he holds the position of CTO. His specific managerial responsibilities cover production, research and development, quality control, environment, safety, maintenance, and procurement.


Our product BRI.Screw is the result of eight years of preclinical research, combined with state-of-the-art materials.

Clinical Trials

We will start our clinical first-in-man trials shortly.

Patient Safety

BRI.Tech attaches great importance to patient safety – that is why we use highly pure elements the human body is accustomed to and can readily deal with. To rule out the risk of complications, we make sure that the concentrations of magnesium, calcium, and zinc set free during degradation never exceed the recommended level.


Our implants are currently undergoing the certification process according to ISO 13485.

Leave a message to keep in touch

We will let you know as soon as BRI.Screw is commercially available for clinical use.